Life Sciences Insights

31 July 2006

Welcome to the July edition of Clayton Utz Life Sciences Insights, in which we'll look at significant regulatory developments, notably the new Medicines Australia Code of Conduct and the first Consultation Forums on ANZTPA.

We focus on the global implications of the UK TGN1412 clinical trial and the impact for the life sciences sector of the recent "wrongful life" cases decided by the High Court.

As usual you will also find a round up of recent developments in Patent law and events of interest overseas.

STOP PRESS!

ACCC authorises new Medicines Australia Code of Conduct - A drive for increased transparency

Once weekly method of treatment not a patentable invention

By Nicholas Tyacke.

Nicholas Tyacke examines a recent decision which held that a once-a-week treatment could not be patented.

Is an injunction restraining further infringement automatic when a patent is held infringed?

By Nicholas Tyacke and Bharti Sharma.

US courts traditionally grant permanent injunctions to stop further patent infringements, but as Nicholas Tyacke and Bharti Sharma show, this is no longer the case.

Patent quips: Edited by Wayne Condon

By Wayne Condon .

In brief: New Zealand to introduce an experimental use exception to patent infringement, and the UK Lipitor litigation.
Key Contacts

To view claytonutz.com correctly, you should upgrade your browser

Download Google Chrome
Download Firefox
Download Safari
Download Internet Explorer